The Westlake Village, Calif.-based biopharmaceutical company filed for Chapter 11 bankruptcy in September after several of its drugs failed to gain approval.
The company, founded in 2010, had hoped to sell itself and restructure but didn’t receive any bids for the whole company. It sold its topical photoparticle therapy assets to Sebacia, a dermatology company, for $1.7 million, according to Bankrupt Company News.
Sienna, which focused on immunology and inflammation treatments, reportedly borrowed hundreds of millions of dollars for research and development, but was never able to bring one of its products to market or generate any revenue.
Read the full article here.
More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
